BioXcel Therapeutics
BTAI
BTAI
83 hedge funds and large institutions have $287M invested in BioXcel Therapeutics in 2022 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 28 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
18% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 28
Holders
83
Holding in Top 10
–
Calls
$3.21M
Puts
$1.35M
Top Buyers
| 1 | +$18.8M | |
| 2 | +$10.9M | |
| 3 | +$6.49M | |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$5.37M |
| 5 |
Vontobel Holding
Zurich,
Switzerland
|
+$1.32M |
Top Sellers
| 1 | -$2.79M | |
| 2 | -$1.05M | |
| 3 | -$879K | |
| 4 |
Goldman Sachs
New York
|
-$861K |
| 5 |
Two Sigma Advisers
New York
|
-$758K |